CSL (ASX:CSL) share price trades flat despite annual R&D update

Here’s what CSL is working on…

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

The CSL Limited (ASX: CSL) share price is trading broadly flat on Tuesday morning following the release of its annual research and development (R&D) update.

At the time of writing, the biotherapeutics company’s shares are fetching $294.15.

CSL share price flat following R&D update

During FY 2021, CSL invested more than US$1 billion in its R&D activities across six therapeutic areas, four scientific platforms, and two businesses.

Management notes that there were a number of highlights during the period. These include:

The Seqirus business advancing its first-of-its-kind adjuvanted, cell-based seasonal influenza vaccine (aQIVc) and increasing its work on its self-amplifying mRNA (sa-mRNA) development program. In fact, earlier this month, the Biomedical Advanced Research and Development Authority (BARDA) awarded Seqirus a multi-year contract to provide clinical development services to evaluate the safety, immunogenicity, and dose-sparing capability of two H2Nx influenza vaccine candidates. One is using a combination of Seqirus’ FDA-licensed cell-based and adjuvanted technologies, and the other is using its next generation sa-mRNA platform.

CSL has started a new collaboration with the Walter and Eliza Hall Institute for Medical Research (WEHI). This is one of the most prominent medical research and medicine development organisations in Australia. The two parties will work together to create a Centre for Biologic Therapies.

Another item highlighted by management is the impending Phase III study of 4-Factor Prothrombin Complex Concentrate to improve survival rates in traumatic injury and acute major bleeding. In addition, the company notes that the VANGUARD Phase III clinical trial for Garadacimab, a treatment in hereditary angioedema (HAE), has enrolled its last patient two months ahead of schedule. Recruitment from the AEGIS-II Phase III study of CSL112 (ApoA-1) for treatment of acute coronary syndrome is also progressing despite COVID-19 impact on clinical trial sites and patients.

Finally, on the licence front, CSL revealed that preparations are underway for EtranaDez, a gene therapy for haemophilia B, to submit a Biologics Licence Application for the US and Marketing Authorisation Application for the EU.

Management commentary

CSL’s Executive Vice President, Head of R&D, and Chief Medical Officer, Dr. Bill Mezzanotte, commented: “We continue to evolve as a leading plasma-based biotechnology company with purposeful diversity in therapeutic areas, scientific platforms and strategic alliances.”

“We are continuing to invest in our core plasma business while also enhancing our other scientific platforms to better deliver on our promise to discover, develop and provide innovations that save and improve lives around the world,” he added.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News